Sarepta insider has 21,423 shares withheld for taxes

Sarepta’s R&D and Tech Ops president had shares withheld to cover taxes on RSU vesting, leaving a direct holding of 203,900 shares.

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. (SRPT) reported that Louise Rodino-Klapac, President, R&D and Tech Ops, had 21,423 shares of common stock withheld on September 4, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on September 3, 2025. This was a disposition of shares for tax payment rather than an open‑market sale, and no Rule 10b5-1 trading plan is reported. After this withholding, she directly held 203,900 shares of Sarepta common stock.

Insider Trade Summary

Tax Withholding: 21,423 shares

Tax Withholding 1 txn

Insider Rodino-Klapac Louise

Role President, R&D and Tech Ops

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	21,423	$22.22	$476K

Holdings After Transaction: Common Stock — 203,900 shares (Direct)

Footnotes (1)

1. F1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025.

Key Figures

Shares withheld for taxes: 21,423 shares Per-share value for withholding: $22.22 per share Shares held after transaction: 203,900 shares

3 metrics

Shares withheld for taxes 21,423 shares Common stock withheld on September 4, 2026 to satisfy tax withholding obligations on RSU vesting

Per-share value for withholding $22.22 per share Value assigned to the 21,423 shares withheld for tax obligations

Shares held after transaction 203,900 shares Direct holdings of Sarepta common stock by Louise Rodino-Klapac after September 4, 2026 transaction

Key Terms

restricted stock units, tax withholding obligations, vesting

3 terms

restricted stock units financial

"related to vesting of restricted stock units granted on September 3, 2025"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"Shares were withheld by the Company to satisfy tax withholding obligations"

vesting financial

"tax withholding obligations related to vesting of restricted stock units"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SRPT report for Louise Rodino-Klapac?

Sarepta Therapeutics reported that 21,423 shares of common stock were withheld on September 4, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units granted on September 3, 2025.

Was the SRPT insider transaction an open-market sale?

No. The filing states that the 21,423 shares were withheld by the company to satisfy tax withholding obligations tied to restricted stock unit vesting, rather than sold in the open market.

How many SRPT shares does Louise Rodino-Klapac hold after this transaction?

Following the September 4, 2026 tax-withholding transaction, Louise Rodino-Klapac directly held 203,900 shares of Sarepta Therapeutics common stock, according to the reported post-transaction holdings.

What price per share is associated with the SRPT tax-withholding transaction?

The tax-withholding disposition of 21,423 shares of Sarepta common stock is reported at $22.22 per share, which is used to value the shares withheld to cover the tax obligations on the RSU vesting.

Was a Rule 10b5-1 plan involved in this SRPT insider transaction?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with this tax-withholding transaction for Louise Rodino-Klapac.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 08:01 PM EDT Accepted by SEC EDGAR 09/08/2026 - 08:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodino-Klapac Louise

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D and Tech Ops

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2026		F(1)		21,423	D	$22.22	203,900	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)